Ligand Pharmaceuticals Inc
LGND· Nasdaq
LGNDLigand Pharmaceuticals Inc
Filed Feb 28, 2025 · 10-K · 59 days after period end · 0000886163-25-000012
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $42.81M | $28.10M | $50.38M | $56.40M |
| Net Income | -$31.09M | $18.19M | -$17.49M | -$5.42M |
| EPS Diluted | — | — | -$0.86 | -$0.19 |
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 28, 2025 · 59 d after period end
